Combining innate immunity with radiation therapy for cancer treatment: Commentary on Mason et al., p. 361

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 7-11

  Czerniecki, Brian J ^a   Koski, Gary K ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; RADIOSENSITIZING AGENT; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DROSOPHILA; DRUG MECHANISM; HUMAN; INNATE IMMUNITY; MOLECULAR CLONING; NONHUMAN; NOTE; PRIORITY JOURNAL; RADIOSENSITIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; COMBINED MODALITY THERAPY; CPG ISLANDS; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; RADIOTHERAPY; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 11344250221     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (25)

1. Mason KA, Ariga H, Neal R, et al. Targeting Toll-like receptor 9 with CpG Oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005;11:361-69.
2. Allen PM, Strydom DJ, Unanue ER. Processing of lysozyme by macrophages: identification of the determinant recognized by two T cell hybridomas. Proc Natl Acad Sci U S A 1984;81:2489-93.
3. Bjorkman PJ, Saper MA, Samraoui B, et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-8.
4. Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302:575-81.
5. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987;49:273-80.
6. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;65:302-19.
7. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-30.
8. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune system. Curr Opin Immunol 1997;9:4-9.
9. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spazel/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-83.
10. Williams MJ, Rodriguez A, Kimbrell DA, et al. The 18-wheeler mutation reveals complex antibacterial gene regulation in Drosophila host defense. EMBO J 1997;16:6120-30.
11. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7.
12. Alexopoulou L, Holt AC, Mezhitov R, et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-8.
13. Poltorak A, He S, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tlr4 gene. Science 1998;282:2085-8.
14. Schwander R, Dziarski R, Wesche H, et al. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406-9.
15. Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognized bacterial DNA. Nature 2000;408:740-5.
16. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004;279:19008-17.
17. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9.
18. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002;23:375-8.
19. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergistically with CD40 ligand induces high amounts of IL-12. Eur J Immunol 2001;31:3026-37.
20. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94.
21. Chakraborty M, Abrams SI, Coleman CN, et al. External beam irradiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T cell killing. Cancer Res 2004;64:4328-37.
22. Kandimalla ER, Zhu FG, Bhagat L, et al. Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs. Biochem Soc Trans 2003;31:654-8.
23. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via Tpll-like receptor 7 and 8. Science 2004;303:1526-9.
24. Koski GK, Kariko K, Xu S, et al. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 2004;172:3989-93.
25. Xu S, Koski GK, Faries M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12 dependent-mechanism. J Immunol 2003;171:2251-62.